Literature DB >> 2538766

The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex.

J M Stirling1, A J Cross, A R Green.   

Abstract

The high affinity binding of the phencyclidine derivative [3H]TCP to cortical membranes of the rat was investigated. In an extensively washed membrane preparation the binding of [3H]TCP was enhanced in the presence of L-glutamate and NMDA. The stimulation of the binding of [3H]TCP by L-glutamate was inhibited competitively by AP5 and non-competitively by MK801. The binding of [3H]TCP was also enhanced in the presence of glycine; this effect was insensitive to strychnine and inhibited non-competitively by AP5. Saturation experiments demonstrated that MK801 was a competitive inhibitor of the binding of [3H]TCP. These results suggest that [3H]TCP binds to a site similar to that which binds MK801; this site may be associated with the ion channel of the NMDA receptor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538766     DOI: 10.1016/0028-3908(89)90059-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.

Authors:  L Turski; A Huth; M Sheardown; F McDonald; R Neuhaus; H H Schneider; U Dirnagl; F Wiegand; P Jacobsen; E Ottow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

2.  Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations.

Authors:  P Saransaari; S M Lillrank; S S Oja
Journal:  J Neural Transm Gen Sect       Date:  1993

3.  Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5HT2 serotonin receptors in rats.

Authors:  Ottavio Gandolfi; Manuela Voltattorni; Renato Gaggi; Rossella Dall'Olio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-13       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.